Compounds > irinotecan
Page last updated: 2024-08-24

irinotecan and cyc 202

irinotecan has been researched along with cyc 202 in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's2 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Abal, M; Bras-Goncalves, R; De Cremoux, P; Fsihi, H; Judde, JG; Louvard, D; Magdelenat, H; Poupon, MF; Robine, S1
Ardelt, MA; Brandl, L; De Toni, EN; Ehrlich, SM; Gerbes, AL; Kirchner, T; Lehr, T; Liebl, J; Mayr, D; Vollmar, AM; Zahler, S1

Other Studies

3 other study(ies) available for irinotecan and cyc 202

ArticleYear
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Enhanced sensitivity to irinotecan by Cdk1 inhibition in the p53-deficient HT29 human colon cancer cell line.
    Oncogene, 2004, Mar-04, Volume: 23, Issue:9

    Topics: Camptothecin; CDC2 Protein Kinase; Cell Cycle; Cyclin B; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Enzyme Activation; Enzyme Inhibitors; HT29 Cells; Humans; Irinotecan; Mutation; Purines; Roscovitine; Tumor Suppressor Protein p53

2004
Targeting cyclin dependent kinase 5 in hepatocellular carcinoma--A novel therapeutic approach.
    Journal of hepatology, 2015, Volume: 63, Issue:1

    Topics: Animals; Antineoplastic Agents; Camptothecin; Carcinoma, Hepatocellular; Cyclin-Dependent Kinase 5; Cyclin-Dependent Kinases; Female; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Liver Neoplasms; Mice; Mice, SCID; Purines; RNA, Neoplasm; Roscovitine; Treatment Outcome

2015